key: cord-0716874-eaobb6re authors: Sharma, R.; Anand, A. title: The Effect of Pandemic Prevalence on the Reported Efficacy of SARS-CoV-2 Vaccine Candidates: A Systematic Review and Meta-analysis date: 2021-06-07 journal: nan DOI: 10.1101/2021.06.05.21258394 sha: ed01be2f6388fa9ea00b8792a3cf1e00f69c059c doc_id: 716874 cord_uid: eaobb6re Abstract Importance The efficacy of SARS-CoV-2 vaccine candidates reported in Phase 3 trials varies from ~45% to ~95%. It is important to explain the reasons for this heterogeneity. Objective To test the hypothesis that the efficacy of SARS-CoV-2 vaccine candidates falls with increasing prevalence of the COVID-19 pandemic. Data Sources ClinicalTrials.gov, WHO, McGill and LSHTM trackers of COVID-19 candidate vaccines, peer reviewed publications, and press releases were searched until March 31st, 2021. Study Selection All RCTs reporting efficacy outcomes from Phase 3 trials till March 31st, 2021 were included. Of the 11 vaccine candidates that had started their Phase 3 trials by November 1, 2020. Phase 3 efficacy outcomes were available for 8 vaccine candidates. (PROSPERO CRD42021243121). Data Extraction and Synthesis Both authors independently extracted the data required from identified sources, using PRISMA guidelines. The analysis included all RCTs reported in peer reviewed publications and publicly available sources. A random effects model with restricted maximum likelihood estimator was used to summarize the treatment effects. Cochrane Risk of Bias Assessment Tool was used to assess risk of bias. Certainty of evidence was assessed using the GRADE tool. Main Outcomes and Measures SARS-CoV-2 infections per protocol in vaccine and placebo groups, risk ratio, prevalence of the COVID-19 infection rate in the populations where the Phase 3 trials were conducted. Results 8 vaccine candidates had reported efficacy data from a total of 20 independent Phase 3 trials, representing a total of 221,968 subjects, 453 infections across the vaccinated groups and 1,554 infections across the placebo groups. The overall estimate of the risk-ratio is 0.24 (95% CI, 0.17-0.34, p < 0.01), with an I2 statistic of 88.73%. The meta-regression analysis with pandemic prevalence as the moderator explains almost half the variance in risk ratios across trials (R2=49.06%, p<0.01). Conclusion and Relevance Pandemic prevalence explains almost half of the between-trial variance in reported efficacies. Efficacy of SARS-CoV-2 vaccine candidates declines as the pandemic prevalence increases. The SARS-CoV-2 pandemic has generated an unprecedented effort towards developing vaccines to halt the pandemic. As of March 31, 2021, 8 vaccine candidates had published efficacy data from a total of 20 independent Phase 3 trials (Table 1) [1] [2] [3] [4] [5] . Efficacies reported by the vaccine candidates range from 45% to 95%. Those differences could be due to various sources of heterogeneity between trials [6] [7] [8] . At this stage of the vaccine development and emergency use authorization of vaccines based on results of Phase 3 trials, it is important to analyse the available data and account for the effect of potential sources of heterogeneity on vaccine efficacy. An important source of between-trial heterogeneity that could explain the differences in the efficacies observed across trials is the prevalence of the pandemic in the populations where the trials were conducted [6] [7] [8] [9] . The prevalence of the SARS-CoV-2 pandemic has varied across locations and over time. As an example, the prevalence reported in national testing programs has varied from near zero in New Zealand to over 40% in countries such as Mexico and Argentina 10 . Prevalence within countries have also varied over time. For instance, prevalence in the US has varied from a low of 4.0%-5.5% over June 2020 to a high of 10.6%-13.1% over December 2020 10 . Efficacies observed in trials conducted across different countries, and even within a country across different time periods are likely to vary on account of the extent pf prevalence. Reported efficacies have influenced decisions in critical areas, including those related to public health decisions and individual decisions leading to vaccine hesitancy 11 . To better guide those decisions, we conducted a systematic review and meta-analysis of the efficacy data available from Phase 3 trials. Importantly, we test the hypothesis that as the prevalence of the SARS-CoV-2 pandemic across the trials increases, the observed efficacy will decrease. This study is a systematic review and meta-analysis of the efficacy data reported in Phase 3 trials of SARS-CoV-2 vaccine candidates. The meta-analysis reports an overall summary estimate of the riskratio and conducts a meta-regression to test the effect of between-trial differences in prevalence of the SARS-CoV-2 pandemic on efficacies reported across trial sites. Vaccine candidates were included in this study if they reported efficacy results from Phase 3 randomised controlled trials. Results of Phase 3 trials reported till March 31, 2021 were included in the analysis. Phase 3 clinical trials of vaccine candidates are being conducted by the vaccine manufacturers only. We started our search by identifying vaccine candidates that had registered Phase 3 trials, following PRISMA guidelines. Given the high level of interest in the development of SARS-CoV-2 vaccines, such information is widely shared by the manufacturers and tracked by multiple reliable sources [1] [2] [3] . In particular, the WHO maintains a tracker database that compiles detailed information on the SARS-CoV-2 vaccine candidate landscape, tracks vaccine candidates in development, and regularly updates progress on registered trials that are underway: "To ensure the latest information is available, the landscape will be updated twice a week (Tuesday and Friday, 17:00 CET) by searching, gathering and cross-checking data from multiple sources such as the Cochrane vaccine mapping tool, PubMed, ClinicalTrials.gov, WHO ICTRP and from a network of researchers and industry for new candidate vaccines by screening registered trials for clinical information. Where data is missing, … we supplement information gathered from press or public releases" 1 . Similar information is compiled independently by McGill University's 2 and the LSHTM's Vaccine Centre's 3 COVID19 Vaccine Tracker websites. Given the rigorous process followed by those websites, which includes searching of key databases such as PubMed and ClinicalTrials.gov, we relied on those sources to identify vaccine candidates that had progressed to Phase 3 trials. The data on vaccine candidates from the three websites was aggregated by RS to compile a master list of vaccine candidates (Supplement, eTable 1). A total of 26 unique vaccine candidates that had progressed to Phase 3 trials were identified. There was 100% concordance between the three tracker websites regarding vaccine candidates currently in Phase 3 trials (Supplement, eTable 1). RS then searched the information available on the three tracker websites, and ClinicalTrials.gov to identify the start dates of the Phase 3 trials for each vaccine candidate. Given the time lag between the start of Phase 3 trials and the reporting of efficacy results, trials that had not started by November 1, 2020 were excluded from a further search of results of Phase 3 trials. This left a total of 11 vaccine candidates to be searched for the results of efficacy data from Phase 3 trials. AA independently validated every step of the search, and the master list of vaccine candidates through reference to additional sources (Supplement, eTable 1). No discrepancies were located, and no additional vaccine candidates were located. RS then searched for original sources where efficacy results of the Phase 3 trials were reported. The progress of vaccine candidates through various trial stages is also of intense public interest and receives unprecedented public scrutiny 1-3 . RS then located links to Phase 3 registered trials from all three tracker websites. Source publications reporting efficacy data for four vaccine candidates were identified on ClinicalTrials.gov (AstraZeneca, Gamaleya, Moderna, and Pfizer, see Figure 1 ). RS then visited the websites of the remaining vaccine manufacturers, which yielded source documents for another four vaccine candidates (Bharat Biotech, Janssen, Novavax, and Sinovac). No efficacy data could be located for the other 3 vaccine candidates, which are from Sinopharm and CanSino, who have chosen not to publicly report the data 22 (Supplement, eTable 2). The search identified 8 vaccine candidates that had reported efficacy data. Table 1 lists the efficacyrelated data from 20 independent Phase 3 trials reported by those 8 vaccine candidates, viz. AstraZeneca AZD1222 (4 trials), Bharat Biotech Covaxin, Janssen JNJ-78436735 (8 trials), Moderna mRNA-1273, Novavax NVX-CoV2373 (2 trials), Pfizer/BioNTech BNT162b2, and Sinovac CoronaVac (2 trials). Additional details regarding the trials are reported in Supplement, eTable 3. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Pandemic prevalence associated with a trial is estimated from the country-wise data on the SARS-CoV-2 positivity rates reported on Oxford University's 'Our World in Data' portal 10 . The portal reports daily country-wise data for all countries, where available, on the number of people who tested positive for the SARS-CoV-2 infection in the country's national SARS-CoV-2 testing program 10 . Daily SARS-CoV-2 positive rates corresponding to the duration of each trial were extracted from the portal. The prevalence of the SARS-CoV-2 pandemic associated with each trial was computed as the average of the daily positivity rate prevailing over the duration of the trial ( Table 2) . Actual start dates for each trial were taken from the trials' registration data on ClinicalTrials.gov and corroborated with the information reported in the peer reviewed documents, company reports and company press releases. The SARS-CoV-2 positivity rates across countries are not directly comparable due to the different protocols and practices across the different national SARS-CoV-2 testing programs 10 . Some of the key differences across countries include different testing regimes, different rates of testing, the different standards of testing, and different reporting practices across countries 10 . To address that limitation, we transformed the raw SARS-CoV-2 positivity rates into ranks for use as a moderator in the metaregression; while the raw SARS-CoV-2 positivity rates may include a large error component, the ranks are likely to carry a much smaller error component. The study was registered at PROSPERO (Registration Number CRD42021243121). -- Table 2 : Prevalence of the SARS-CoV-2 pandemic associated with each trial -- The overall estimate of the risk-ratio (Forest plot reported in Figure 2 ) is 0.24 (p<0.01; 95% CI: 0.17, 0.34). This equates to an overall efficacy of 76%. -- Figure 2 : Forest Plot-- The I 2 statistic is 88.73%, suggesting that the extent of heterogeneity is considerable, and that a high proportion of the total variance is due to between-study heterogeneity 24 . This justifies attempts to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.05.21258394 doi: medRxiv preprint explain the heterogeneity using between-study differences which, in our case, is prevalence of the pandemic. Heterogeneity (L'Abbe plot, Supplement eFigure 1) is formally explored via meta-regression with pandemic prevalence as the moderator. A meta-regression of the log risk ratio on pandemic prevalence reports that almost half of the variance in log risk ratios across trials is explained by pandemic prevalence (R 2 =49.06%, p<0.01) ( Table 3 ). The inverse relationship between pandemic prevalence and observed vaccine efficacy hypothesised in this study is supported. The funnel plot (Supplement, eFigure 2) shows no visually obvious small-study effect on the findings. Results of the Egger test report no small-study effects on the findings (beta1 = 0.28, p = 0.73), supporting the visual interpretation (Supplement, eTable 4). Results of nonparametric trim-and-fill analysis of publication bias reports no publication bias due to missing studies; estimated number of imputed studies = 0 (Supplement, eTable 5). Sensitivity analyses were conducted to analyse if the result of the meta-regression is sensitive to the inclusion of multiple trials for the Janssen vaccine (8 trials) or the AstraZeneca vaccine (4 trials). Two meta-regressions were run, one with an additional dummy variable for the Janssen vaccine, and the other with an additional dummy variable for the AstraZeneca vaccine. In both cases, the regression coefficient for pandemic prevalence was significant, while the coefficients for the dummy variable (Janssen/AstraZeneca) were non-significant (Supplement, eTables 6 and 7). Another sensitivity analysis was run excluding the data points for Brazil. This was done as the daily SARS-CoV-2 positivity rate for Brazil was not available as its rank of pandemic prevalence was estimated indirectly (see Table 2 , Note c). Excluding those three trials does not change the result of the meta-regression; the effect of pandemic prevalence remains significant (R 2 = 44.56%, p < 0.01) (Supplement, eTable 8). Risk of bias was assessed as low using the Cochrane tool, while certainty of evidence was assessed as high using GRADE (Supplement, eTables 9,10). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.05.21258394 doi: medRxiv preprint The meta-analysis (Forest plot, Figure 2 ) finds that the overall risk ratio across all 8 vaccines, reporting a total of 20 trials, is 0.24 (p<0.01; 95% CI: 0.17, 0.34), corresponding to an overall efficacy of 76%. The overall efficacy, 76%, is substantially higher than the threshold of 30% often considered as acceptable in Phase 3 trials 16, 19 . Overall, the vaccines demonstrate high efficacy. The results support our hypothesis that increasing pandemic prevalence leads to lower efficacy of SARS-CoV-2 vaccine candidates ( Table 3 , R 2 =49.06%, p<0.05). Support for the hypothesis is robust, and not sensitive to potential sources of validity threats. The inclusion of multiple trials for the Janssen and AstraZeneca vaccine candidates does not affect the results of the meta-regression reported in Table 3 . The finding reported in Table 3 is also robust against the inclusion of trials conducted in Brazil. The key implication of this study is that a substantial proportion of the differences in efficacy observed across trials can be attributed to the prevalence of the SARS-CoV-2 pandemic across trial sites. This one source of heterogeneity explains almost 50% of the variance in efficacies observed across trials. There are a number of other sources of heterogeneity that occur across Phase 3 trials of the SARS-CoV-2 vaccine candidates too, including, but not limited to doses, interval between doses and the definition of primary endpoints 7, 8 . Future research could investigate the effect of other between-trial differences that could explain additional heterogeneity in observed efficacy. Table 3 reports that the I 2 statistic for residual heterogeneity is 79.3%. This suggests that it is quite likely that the residual heterogeneity could be explained by those additional between-trial differences. The meta-regression analysis (Table 3) reports that vaccine efficacy falls as pandemic prevalence increases. A key implication of this finding is that the proper interpretation of efficacies reported by vaccine candidates needs to account for the effect of pandemic prevalence. The finding that pandemic prevalence affects vaccine efficacy suggests two implications for the conduct of Phase 3 trials of SARS-CoV-2 vaccine candidates. First, when efficacy results of Phase 3 trials are reported, they should be reported in conjunction with the level of pandemic prevalence All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.05.21258394 doi: medRxiv preprint associated with the trial sites. Given the findings of this meta-analysis, a meaningful interpretation of observed efficacy in Phase 3 trials can only be done in conjunction with the associated data on pandemic prevalence. Second, it suggests that protocols for the design and conduct of Phase 3 trials need to take pandemic prevalence into account. The design of trials should include randomization of trial subjects across locations that vary in the prevalence of the pandemic. Further, for the duration of the Phase 3 trials, manufacturers should monitor pandemic prevalence in all locations where the trials are conducted. A key strength of this study is that it summarizes the entire current publicly available global evidence on the efficacy of SARS-CoV-2 vaccine candidates. It is also a strength of this study that it can explain almost half the variance in between-trial efficacies with one moderator variable only, pandemic prevalence. That data on pandemic prevalence is obtained from sources independent of the trials, is another strength of this meta-analysis. The overall sample is small, 20 trials across 8 vaccine candidates. Efficacy data on three other vaccine candidates that have completed Phase 3 trials and are currently approved for use is not publicly available and could not be included in this meta-analysis. All trials are multi-location, and a few are multi-country too, e.g., Pfizer/BioNTech's trial conducted in the US, Chile and Peru (see Table 2 , Note a). In the absence of data on the exact locations of those trials and the number of subjects in the trial at each location, we have used country-level data to rank each trial on pandemic prevalence. This assumption necessarily introduces an element of error in estimating pandemic prevalence. To some extent, that effect is mitigated in our meta-regression by employing rank of pandemic prevalence as the moderator variable. Future Phase 3 trials could be required to report a location-level analysis to provide better insights into the efficacy results of Phase 3 trials. Pandemic prevalence has a significant negative effect on efficacies observed across Phase 3 trials of SARS-CoV-2 vaccine candidates; trials conducted in locations with low pandemic prevalence reported higher efficacies as compared to trials conducted in high pandemic prevalence locations. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All datasets generated and analysed are available in the Article and the Supplement. There was no funding source for this study. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Supplement, eTable 3) . a For its US trial, AstraZeneca reports efficacy, total number of participants, split ratio between vaccinated and placebo groups, and the total number of infections. The infected numbers in each group were not reported, however, the data provided by AstraZeneca was sufficient for those numbers to be computed. Turkey July -Dec (2020) 4.08 3 a Average daily SARS-CoV-2 positivity rates in the US only was considered for this trial. The break-up of subjects across the three countries is not available, however, the number of centers running the trials in Chile and Peru was much smaller as compared to the number of centers in the US. b The lowest rank corresponds to the lowest 'Average daily SARS-CoV-2 positivity rate'. Ties were awarded the same rank. c Daily raw SARS-CoV-2 positive rate data was not available for Brazil 10 . The World Health Organization's website, https://worldhealthorg.shinyapps.io/covid/ mentions that in Week 37 of the pandemic (6 th -12 th Sep 2020), the positivity rate in Brazil was 63.1%. This is substantially higher than the next highest rate (41.53 for Mexico, Rank 15). That enables us to assign the highest rank (16) to Brazil, even in the absence of specific data on Brazil's positivity rate. This is consistent with all the other information on WHO's website which shows that the pandemic in Brazil is far worse than that in any other country (https://worldhealthorg.shinyapps.io/covid/). It can also be inferred from Janssen 9 (Figure 10 , p.55) that Brazil had the highest sustained rate of COVID-19 infections in the placebo group as compared to Argentina, Colombia, USA and South Africa over the period of the trial for which efficacy data reported, indicating that the prevalence of the pandemic in Brazil was higher than all the other countries. Rajeev Sharma, Abhijith Anand Apart from the minor discrepancies reported in a, and b above, there was 100% correspondence between the three sources regarding the 26 vaccine candidates in Phase 3 trials listed in Table S2 "So far, however, researchers have released no corroborating data to the publicnot in patents filed for the vaccine or in any other sources. Additionally, their claims about EpiVacCorona's efficacy contradict the findings of an independent laboratory that analyzed blood samples from clinical-trial volunteers and found no neutralizing antibodies." (https://meduza.io/en/feature/2021/03/23/epivaccorona-srace-to-the-finish-line) "The published research concerns EpiVacCorona's combined Phase I and II trials (involving 14 and 86 volunteers, respectively), meaning that the data reflects only the drug's short-term safety and side effects, as well as its ability to provoke an immune response in patients. These experiments weren't designed to test the vaccine's effectiveness, which can't be assessed until the end of Phase III, which involves 3,000 participants." (https://meduza.io/en/feature/2021/03/27/sputnNik-v-s-ugly-cousin) Medicago Inc. N N "pleased to announce the start of Phase 3 clinical testing" https://www.medicago.com/en/medi a-room/medicago-and-gsk-startphase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.05.21258394 doi: medRxiv preprint eFigure 2: L'Abbe' plot to explore heterogeneity eFigure 3: Funnel Plot All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 7, 2021. 2. Gamaleya deviated from the original protocol by changing the primary outcome of the trial midway through the trial. Specifically, the end point was taken as 21 days after the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.05.21258394 doi: medRxiv preprint first dose, rather than 14 days after the second dose in the original protocol. The issue has been reported in 8 and has been peer reviewed. All other aspects of RCT were per protocol. The deviation from protocol does not make a material difference to the overall risk of bias assessment. 3. For AstraZeneca (US, Chile and Peru trial), Bharat Biotech and Sinovac, the data on primary outcomes are taken from the company press releases. Results from their Phase 3 trials have not been publicly reported or peer reviewed. However, both vaccines had their Phase 3 trial protocols approved by their respective regulatory authorities. Further, all three vaccines have been approved for use by various national authorities. The overall risk of bias is considered as low. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.05.21258394 doi: medRxiv preprint World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines COVID19 Vaccine Tracker website An interactive website tracking COVID-19 vaccine development. Lancet Glob Health; epub SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines Efficacy Data Updates from Novavax' Protein-based Vaccine Candidate Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines Force of infection: A determinant of vaccine efficacy Sponsor briefing document -vaccines and related biological products advisory committee meeting date Coronavirus Pandemic (COVID-19 Detroit mayor rejects initial J&J vaccine shipment, saying Pfizer and Moderna are 'the best Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet AZD1222 US Phase III primary analysis confirms safety and efficacy Bharat Biotech Announces Phase 3 Results of COVAXIN®: India's First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81% Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Summary of Clinical Trail Data of Sinovac's COVID-19 Vaccine Sinovac Announces Phase III Results of Its COVID-19 Vaccine China's vaccine diplomacy stumbles as clinical trial data remains absent Introduction to Meta-Analysis Cochrane Handbook for Systematic Reviews of Interventions version 6 References 1. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines COVID19 Vaccine Tracker website An interactive website tracking COVID-19 vaccine development. Lancet Glob Health; epub SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines COVID-19 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Sponsor briefing document -vaccines and related biological products advisory committee meeting date Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Efficacy Data Updates from Novavax' Protein-based Vaccine Candidate Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials Summary of Clinical Trail Data of Sinovac's COVID-19 Vaccine Note: a Results of two Phase 3 trials reported by Sinovac, and one each by Bharat Biotech, and the AstraZeneca (US, Chile, Peru trial) were not peer reviewed. However, as per the GRADE assessment above (eTable 9), the overall risk of bias for the non-peer reviewed studies is assessed to be low.